DE102010043733A1 - Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen - Google Patents

Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen Download PDF

Info

Publication number
DE102010043733A1
DE102010043733A1 DE102010043733A DE102010043733A DE102010043733A1 DE 102010043733 A1 DE102010043733 A1 DE 102010043733A1 DE 102010043733 A DE102010043733 A DE 102010043733A DE 102010043733 A DE102010043733 A DE 102010043733A DE 102010043733 A1 DE102010043733 A1 DE 102010043733A1
Authority
DE
Germany
Prior art keywords
diseases
thrombotic
pegylated liposomes
unloaded
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102010043733A
Other languages
German (de)
English (en)
Inventor
Beate Kehrel
Martin Brodde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OXPROTECT GmbH
Original Assignee
OXPROTECT GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OXPROTECT GmbH filed Critical OXPROTECT GmbH
Priority to DE102010043733A priority Critical patent/DE102010043733A1/de
Priority to PCT/EP2011/069861 priority patent/WO2012062867A1/fr
Publication of DE102010043733A1 publication Critical patent/DE102010043733A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE102010043733A 2010-11-10 2010-11-10 Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen Withdrawn DE102010043733A1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE102010043733A DE102010043733A1 (de) 2010-11-10 2010-11-10 Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
PCT/EP2011/069861 WO2012062867A1 (fr) 2010-11-10 2011-11-10 Liposomes pégylés non chargés destinés à une utilisation comme médicament pour la prophylaxie et la thérapie de maladies hémorragiques et thromboemboliques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010043733A DE102010043733A1 (de) 2010-11-10 2010-11-10 Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen

Publications (1)

Publication Number Publication Date
DE102010043733A1 true DE102010043733A1 (de) 2012-05-10

Family

ID=44983527

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102010043733A Withdrawn DE102010043733A1 (de) 2010-11-10 2010-11-10 Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen

Country Status (2)

Country Link
DE (1) DE102010043733A1 (fr)
WO (1) WO2012062867A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017220099A1 (fr) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants aux propriétés de drainage modifiées

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689428A1 (fr) 1993-03-23 1996-01-03 Sequus Pharmaceuticals, Inc. Composition contenant des effecteurs a circulation amelioree et procede d'utilisation de ladite composition
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6593294B1 (en) 1998-04-27 2003-07-15 Opperbas Holding B.V. Pharmaceutical composition comprising Factor VIII and neutral liposomes
EP1328289A2 (fr) 2000-10-20 2003-07-23 Beate Kehrel Proteines oxydees, leur effet biologique et mesures therapeutiques et diagnostiques decoulant du mecanisme d'action, de l'utilisation de ces proteines ou de leur inhibition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376591B2 (ja) * 1991-08-28 2003-02-10 三菱ウェルファーマ株式会社 プロテインｃ活性化促進剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689428A1 (fr) 1993-03-23 1996-01-03 Sequus Pharmaceuticals, Inc. Composition contenant des effecteurs a circulation amelioree et procede d'utilisation de ladite composition
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6593294B1 (en) 1998-04-27 2003-07-15 Opperbas Holding B.V. Pharmaceutical composition comprising Factor VIII and neutral liposomes
EP1328289A2 (fr) 2000-10-20 2003-07-23 Beate Kehrel Proteines oxydees, leur effet biologique et mesures therapeutiques et diagnostiques decoulant du mecanisme d'action, de l'utilisation de ces proteines ou de leur inhibition

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T. Simoons ML, Hamm CW; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003 Sep 23; 108(12): 1440-5
Baru M, Carmel-Goren L, Barenholz Y, Dayan I, Ostropolets S, Slepoy I, Gvirtzer N, Fukson V, Spira J. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost. 2005 Jun; 93(6): 1061-8
Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003 Oct 23; 349(17): 1595-604
Brevetti G, Schiano V, Laurenzano E, Giugliano G, Petretta M, Scopacasa F, Chiariello M. Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur Heart J. 2008 Jan; 29(2): 224-30
Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001 Mai; 11(3): 130-5
Coleman LG Jr, Polanowska-Grabowska RK, Marcinkiewicz M. Gear AR. LDL oxidized by hypochlorous acid causes irreversible platelet aggregation when combined with low levels of ADP, thrombin, epinephrine, or macrophage-derived chemokine (CCL22). Blood. 2004 Jul 15; 104(2): 380-9
Graeme J Hankey and John W Eikelboom. Antiplatelet drugs MJA 2003; 178(11): 568-574
Gupta GP and Massagué J. Platelets and metastasis revisited: a novel fatty link J Clin Invest. 2004 December 15; 114(12): 1691-1693
Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest. 1996 Mar 15; 97(6): 1535-44
Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003 Jan; 9(1): 61-7
Jain S, Zuka M, Liu J, Russell S, Dent J, Guerrero JA, Forsyth J, Maruszak B, Gartner TK, Felding-Habermann B, Ware J. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA. 2007 May 22; 104(21): 9024-8
Jurk K, Clemetson KJ, de Groot PG, Brodde MF, Steiner M, Savion N, Varon D, Sixma JJ, Van Aken H, Kehrel BE. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an altemative/backup mechanism to von Willebrand factor. FASEB J. 2003 Aug; 17(11): 1490-2
Jurk K, Kehrel BE. The role of platelets in haemostasis, thrombosis, immune defense and inflammation. Dtsch Med Wochenschr. 2008 May; 133(21): 1130-5
Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann. Intern. Med. 1981; 95: 636-641
Klebanoff SJ. Myeloperoxidase. Proc Assoc Am Physicians. 1999 Sep-Oct; 111(5): 383-9
Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005 May; 77(5): 598-625
Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001 Apr 3; 103(13): 1718-20
Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. Journal of Internal Medicine. J Intern Med. 2008 May; 263(5): 517-27
Miyata Y, Koga S, Takehara K, Kanetake H, Kanda S. Expression of Thrombospondin-derived 4N1K Peptide-containing Proteins in Renal Cell Carcinoma Tissues Is Associated with a Decrease in Tumor Growth and Angiogenesis. Clin Cancer Res. 2003 May; 9(5): 1734-40
Moshe Baru et al.; Pharmaceutical composition comprising Factor VIII and neutral liposomes)
Narizhneva NV, Razorenova OV, Podrez EA, Chef J, Chandrasekharan UM, DiCorleto PE, Plow EF, Topol EJ, Byzova TV. Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J. 2005 Jul; 19(9): 1158-60
Pardridge WM. Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb Protoc. 2010 Apr; 2010(4)
Powell JS, Nugent DJ, Harrison JA, Soni A, Luk A, Stass H, Gorina E. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost. 6(2)(2008): 277-283
Powell JS. Liposomal approach towards the development of a longeracting factor VIII. Haemophilia 13 (Suppl 2)(2007): 23-28
Powell JS. The next generation of anti-haemophilia factor, factor VIII. Long-lasting protection from spontaneous bleeding, are we there yet? Thromb Haemost. 100(2008): 365-6
Re G, Lanzarini C, Vaona I, Pazzaglia M, Palareti G, Bassein L, Guarnieri C. Systemically circulating oxidative species in human deep venous thrombosis. Eur J Emerg Med. 1998 Mar; 5(1): 9-12
Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res. 2007; 120 Suppl 1: S5-9
Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood. 2006 Dec 1; 108(12): 3668-73
Spira J, Plyushch OP, Andreeva TA, Khametova RN. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 2008; 100(3): 429-34
Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr, Hazen SL. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004 Aug 31; 110(9): 1134-9
Volf I, Bielek E, Moeslinger T, Koller F, Koller E. Modification of protein moiety of human low density lipoprotein by hypochlorite generates strong platelet agonist. Arterioscler Thromb Vasc Biol. 2000 Aug; 20(8): 2011-8
Wagner DD, Burger PC. Platelets in inflammation and thrombosis. ArteriosclerThromb Vasc Biol. 2003 Dec; 23(12): 2131-7
Yatuv R, Carmel-Goren L, Dayan I, Robinson M, Baru M. Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells. J Control Release. 2009 Apr 2; 135(1): 44-50
Yatuv R, Dayan I, Carmel-Goren L, Robinson M, Aviv I, Goldenberg-Furmanov M, Baru M. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia. 2008 May; 14(3): 476-83

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
WO2012107567A2 (fr) 2011-02-10 2012-08-16 Oxprotect Gmbh Détection et retrait de protéines/peptides à mauvais repliement
US9316650B2 (en) 2011-02-10 2016-04-19 Oxprotect Gmbh Detection and removal of misfolded proteins/peptides
US10416170B2 (en) 2011-02-10 2019-09-17 Oxprotect Gmbh Detection and removal of misfolded proteins/peptides

Also Published As

Publication number Publication date
WO2012062867A1 (fr) 2012-05-18
WO2012062867A8 (fr) 2012-12-13

Similar Documents

Publication Publication Date Title
Chan et al. Snake venom toxins: toxicity and medicinal applications
Carmona-Ribeiro et al. Novel formulations for antimicrobial peptides
EP3328414B1 (fr) Composition destinée à être utilisée pour favoriser la cicatrisation de plaies
DE19549852B4 (de) Cyclosporin enthaltende Präparate
TW400234B (en) Pharmaceutical compositions for subcutaneous, intramuscular or intradermal administration containing coagulation factor VIII or factor IX and additive
US20160263241A1 (en) Treating Myelomas
EP2310043B1 (fr) Facteur de von willebrand ou facteur viii et facteur de von willebrand destinés au traitement d une coagulopathie induite par des inhibiteurs des thrombocytes
Brenner et al. Endothelial nanomedicine for the treatment of pulmonary disease
Aizik et al. Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases
US6022854A (en) Platelet specific therapeutic compound and method of treating
DE69532066T2 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerosis
Kinhult et al. Effects of probucol on endothelial damage by 5-fluorouracil
DE3141223A1 (de) "oral verabreichbare arzneimittel zur therapie und prophylaxe von haemophilie a"
Maranhão et al. Advances in non-invasive drug delivery for atherosclerotic heart disease
Saikia et al. Silica nanoparticle–endothelial interaction: uptake and effect on platelet adhesion under flow conditions
DE60004015T2 (de) Inhibitoren für homöostase und immunfunktion
Riaz et al. An overview of biomedical applications of choline geranate (CAGE): a major breakthrough in drug delivery
He et al. Artificial high‐density lipoprotein‐mimicking nanotherapeutics for the treatment of cardiovascular diseases
Edwards et al. Neuroprotective cationic arginine-rich peptides (CARPs): an assessment of their clinical safety
Husted New developments in oral antiplatelet therapy
DE102010043733A1 (de) Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
JPH09511216A (ja) ユニラメラリポソーム性のアラキドン酸代謝物剤を用いる治療の方法
Abdul Rasool et al. A narrative review of the potential roles of lipid-based vesicles (vesiculosomes) in burn management
JP2011513496A (ja) アポイクオリン含有組成物及びその使用方法
Candiotti et al. Adverse neurologic reactions to the sting of the imported fire ant

Legal Events

Date Code Title Description
R082 Change of representative

Representative=s name: WEICKMANN & WEICKMANN, 81679 MUENCHEN, DE

Representative=s name: WEICKMANN & WEICKMANN, DE

Representative=s name: PATENTANWAELTE WEICKMANN & WEICKMANN, DE

R082 Change of representative

Representative=s name: WEICKMANN & WEICKMANN, 81679 MUENCHEN, DE

Representative=s name: WEICKMANN & WEICKMANN, DE

Representative=s name: PATENTANWAELTE WEICKMANN & WEICKMANN, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee